BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastro-oesophageal reflux disease in general practice. BMJ 2001;322:344-7. [PMID: 11159660 DOI: 10.1136/bmj.322.7282.344] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Caleiro MTC, Lage LV, Navarro-rodriguez T, Bresser A, Da Costa PA, Yoshinari NH. Radionuclide imaging for the assessment of esophageal motility disorders in mixed connective tissue disease patients: relation to pulmonary impairment. Diseases of the Esophagus 2006;19:394-400. [DOI: 10.1111/j.1442-2050.2006.00598.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
2 Locke GR 3rd. Current medical management of gastroesophageal reflux disease. Thorac Surg Clin 2005;15:369-75. [PMID: 16104127 DOI: 10.1016/j.thorsurg.2005.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
3 Triadafilopoulos G. Endotherapy for GERD: angels and demons. Gastrointestinal Endoscopy 2005;61:668-70. [DOI: 10.1016/s0016-5107(05)00324-x] [Cited by in Crossref: 8] [Article Influence: 0.5] [Reference Citation Analysis]
4 Newton JL. Care of the elderly with gastrointestinal problems in family practice. Best Pract Res Clin Gastroenterol 2001;15:1013-25. [PMID: 11866490 DOI: 10.1053/bega.2001.0255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
5 Nandurkar S, Locke GR, Fett S, Zinsmeister AR, Cameron AJ, Talley NJ. Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community. Aliment Pharmacol Ther. 2004;20:497-505. [PMID: 15339321 DOI: 10.1111/j.1365-2036.2004.02156.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 87] [Article Influence: 5.4] [Reference Citation Analysis]
6 Talley NJ, Moore MG, Sprogis A, Katelaris P. Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. Medical Journal of Australia 2002;177:415-27. [DOI: 10.5694/j.1326-5377.2002.tb04882.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
7 Lucioni C, Mazzi S, Rossi C. Proton pump inhibitors in acute treatment of reflux oesophagitis : a cost-effectiveness analysis. Clin Drug Investig 2005;25:325-36. [PMID: 17532670 DOI: 10.2165/00044011-200525050-00005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 de Wit NJ, de Boer WA, Geldof H, Hazelhoff B, Bergmans P, Tytgat GNJ, Smout AJPM. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?: TREATMENT OF GERD WITH RABEPRAZOLE. Alimentary Pharmacology & Therapeutics 2004;20:451-8. [DOI: 10.1111/j.1365-2036.2004.02096.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
9 Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole: A Review of its Use in the Management of Acid-Related Disorders in the US. Drugs 2002;62:1091-118. [DOI: 10.2165/00003495-200262070-00006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
10 Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ. 2003;326:737. [PMID: 12676842 DOI: 10.1136/bmj.326.7392.737] [Cited by in Crossref: 215] [Cited by in F6Publishing: 192] [Article Influence: 11.3] [Reference Citation Analysis]
11 Wolfe M. Managing gastroesophageal reflux disease: from pharmacology to the clinical arena. Gastroenterology Clinics of North America 2003;32:S37-46. [DOI: 10.1016/s0889-8553(03)00055-4] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
12 Meneghelli UG, Boaventura S, Moraes-Filho JP, Leitão O, Ferrari AP, Almeida JR, Magalhães AF, Castro LP, Haddad MT, Tolentino M, Jorge JL, Silva E, Maguilnik I, Fischer R. Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate. Dis Esophagus 2002;15:50-6. [PMID: 12060043 DOI: 10.1046/j.1442-2050.2002.00225.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol. 2005;17:559-566. [PMID: 15827447 DOI: 10.1097/00042737-200505000-00013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
14 Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs. 2002;62:1503-1538. [PMID: 12093317 DOI: 10.2165/00003495-200262100-00006] [Cited by in Crossref: 101] [Cited by in F6Publishing: 83] [Article Influence: 5.1] [Reference Citation Analysis]
15 Cameron AJ, Lagergren J, Henriksson C, Nyren O, Locke GR 3rd, Pedersen NL. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology. 2002;122:55-59. [PMID: 11781280 DOI: 10.1053/gast.2002.30301] [Cited by in Crossref: 164] [Cited by in F6Publishing: 140] [Article Influence: 8.2] [Reference Citation Analysis]
16 Paulssen EJ, Lindsetmo RO. Long-term outcome of endoluminal gastroplication in the treatment of gastro-oesophageal reflux disease: effect of a second procedure. Scand J Gastroenterol. 2008;43:5-12. [PMID: 18938771 DOI: 10.1080/00365520701514560] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
17 Malfertheiner P, Stanghellini V, Galmiche JP, Jones RH. Review article: managing the dyspeptic patient--an interactive discussion. Aliment Pharmacol Ther. 2001;15 Suppl 2:14-19. [PMID: 11556876 DOI: 10.1046/j.1365-2036.2001.00117.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Ponce J, Vegazo O, Beltrán B, Jiménez J, Zapardiel J, Calle D, Piqué JM; Iberge Study Group. Prevalence of gastro-oesophageal reflux disease in Spain and associated factors. Aliment Pharmacol Ther. 2006;23:175-184. [PMID: 16393295 DOI: 10.1111/j.1365-2036.2006.02733.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
19 Bixquert M. Maintenance therapy in gastro-oesophageal reflux disease. Drugs. 2005;65 Suppl 1:59-66. [PMID: 16335859 DOI: 10.1111/j.1365-2036.2007.03381.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 3.7] [Reference Citation Analysis]
20 van Zyl J, van Rensburg C, Vieweg W, Fischer R. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. Digestion 2004;70:61-9. [PMID: 15297779 DOI: 10.1159/000080130] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
21 Bak YT. Management strategies for gastroesophageal reflux disease. J Gastroenterol Hepatol 2004;19 Suppl 3:S49-53. [PMID: 15324382 DOI: 10.1111/j.1440-1746.2004.03587.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
22 Cammarota G, Masala G, Cianci R, Palli D, Capaccio P, Schindler A, Cuoco L, Galli J, Ierardi E, Cannizzaro O, Caselli M, Dore MP, Bendinelli B, Gasbarrini G. Reflux symptoms in professional opera choristers. Gastroenterology 2007;132:890-8. [PMID: 17383418 DOI: 10.1053/j.gastro.2007.01.047] [Cited by in Crossref: 45] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
23 Talley NJ. Dyspepsia1 1Loren Laine, M.D.Clinical Management EditorUniversity of Southern CaliforniaLos Angeles, California. Gastroenterology 2003;125:1219-26. [DOI: 10.1016/j.gastro.2003.07.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
24 Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol. 2008;23:746-751. [PMID: 18028348 DOI: 10.1111/j.1440-1746.2007.05218.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
25 Salvatore S, Vandenplas Y. Gastro-oesophageal reflux disease and motility disorders. Best Practice & Research Clinical Gastroenterology 2003;17:163-79. [DOI: 10.1016/s1521-6918(02)00146-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
26 Triadafilopoulos G. Bravura for Bravo pH monitoring. Gastrointestinal Endoscopy 2006;63:1051-4. [DOI: 10.1016/j.gie.2006.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Cremonini F, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohort. Neurogastroenterol Motil 2006;18:987-94. [PMID: 17040409 DOI: 10.1111/j.1365-2982.2006.00816.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
28 Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401. [PMID: 19583455 DOI: 10.2165/00003495-200969100-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
29 Assimakopoulos SF, Thomopoulos KC, Louvros E, Theocharis G, Giannikoulis C, Katsakoulis E, Nikolopoulou VN. Changes in Indications for Upper Gastrointestinal Tract Endoscopy and Endoscopic Findings during the Last Fifteen Years in South-Western Greece. The American Journal of the Medical Sciences 2008;336:21-6. [DOI: 10.1097/maj.0b013e31815adeea] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Campo SM. New insights into the treatment of gastroesophageal reflux disease. Expert Opinion on Therapeutic Patents 2005;12:1503-15. [DOI: 10.1517/13543776.12.10.1503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Hungin AP, Raghunath AS, Wiklund I. Beyond heartburn: a systematic review of the extra-oesophageal spectrum of reflux-induced disease. Fam Pract 2005;22:591-603. [PMID: 16024554 DOI: 10.1093/fampra/cmi061] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
32 Thomson ABR, Barkun AN, Armstrong D, Chiba N, White RJ, Daniels S, Escobedo S, Chakraborty B, Sinclair P, Veldhuyzen Van Zanten SJO. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study: ENDOSCOPIC FINDINGS IN DYSPEPSIA PATIENTS. Alimentary Pharmacology & Therapeutics 2003;17:1481-91. [DOI: 10.1046/j.1365-2036.2003.01646.x] [Cited by in Crossref: 167] [Cited by in F6Publishing: 158] [Article Influence: 8.8] [Reference Citation Analysis]
33 Katelaris P, Holloway R, Talley N, Gotley D, Williams S, Dent J; DIGESTIVE HEALTH FOUNDATION OF THE GASTROENTEROLOGICAL SOCIETY OF AUSTRALIA. Gastro-oesophageal reflux disease in adults: Guidelines for clinicians. J Gastroenterol Hepatol 2002;17:825-33. [DOI: 10.1046/j.1440-1746.2002.02839.x] [Cited by in Crossref: 34] [Article Influence: 1.7] [Reference Citation Analysis]
34 Madrazo-de la Garza A, Dibildox M, Vargas A, Delgado J, Gonzalez J, Yañez P. Efficacy and Safety of Oral Pantoprazole 20 mg Given Once Daily for Reflux Esophagitis in Children: . Journal of Pediatric Gastroenterology and Nutrition 2003;36:261-5. [DOI: 10.1097/00005176-200302000-00019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
35 Triadafilopoulos G. Endotherapy and Surgery for GERD. Journal of Clinical Gastroenterology 2007;41:S87-96. [DOI: 10.1097/mcg.0b013e3180322d96] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
36 Talley NJ. Yield of endoscopy in dyspepsia and concurrent treatment with proton pump inhibitors: The blind leading the blind? Gastrointestinal Endoscopy 2003;58:89-92. [DOI: 10.1067/mge.2003.302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
37 Ferrús JA, Zapardiel J, Sobreviela E. Management of gastroesophageal reflux disease in primary care settings in Spain: SYMPATHY I study. Eur J Gastroenterol Hepatol. 2009;21:1269-1278. [PMID: 19474743 DOI: 10.1097/meg.0b013e32832a7d9b] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
38 Mattioli S, Lugaresi ML, Pierluigi M, Di Simone MP, D’Ovidio F. Review article: indications for anti-reflux surgery in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;17 Suppl 2:60-67. [PMID: 12786615 DOI: 10.1046/j.1365-2036.17.s2.4.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
39 McCann SK, Campbell MK, Entwistle VA. Reasons for participating in randomised controlled trials: conditional altruism and considerations for self. Trials 2010;11:31. [PMID: 20307273 DOI: 10.1186/1745-6215-11-31] [Cited by in Crossref: 155] [Cited by in F6Publishing: 150] [Article Influence: 12.9] [Reference Citation Analysis]
40 Rahme E, Hunsche E, Toubouti Y, Chabot I. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: What is the potential impact of the withdrawal of rofecoxib? Arthritis Rheum 2006;55:27-34. [DOI: 10.1002/art.21696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
41 Norisue Y, Onopa J, Kaneshiro M, Tokuda Y. Surfing as a risk factor for gastroesophageal reflux disease. Clin J Sport Med 2009;19:388-93. [PMID: 19741311 DOI: 10.1097/JSM.0b013e3181b8ef41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Miyamoto M, Haruma K, Kuwabara M, Nagano M, Okamoto T, Tanaka M. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine. J Gastroenterol Hepatol. 2007;22:639-644. [PMID: 17444849 DOI: 10.1111/j.1440-1746.2007.04871.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
43 Hughes DA, Bodger K, Bytzer P, de Herdt D, Dubois D. Economic Analysis of On-Demand Maintenance Therapy with Proton Pump Inhibitors in Patients with Non-Erosive Reflux Disease: . PharmacoEconomics 2005;23:1031-41. [DOI: 10.2165/00019053-200523100-00006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
44 Biddle W. Gastroesophageal Reflux Disease: Current Treatment Approaches. Gastroenterology Nursing 2003;26:228-36. [DOI: 10.1097/00001610-200311000-00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
45 Carswell CI, Goa KL. Rabeprazole: an update of its use in acid-related disorders. Drugs. 2001;61:2327-2356. [PMID: 11772142 DOI: 10.2165/00003495-200161150-00016] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
46 Johnson DA. Review of esomeprazole in the treatment of acid disorders. Expert Opinion on Pharmacotherapy 2005;4:253-64. [DOI: 10.1517/14656566.4.2.253] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
47 Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther. 2003;18:587-594. [PMID: 12969085 DOI: 10.1046/j.1365-2036.2003.01745.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
48 Shaw MJ, Crawley JA. Improving health-related quality of life in gastro-oesophageal reflux disease. Drugs 2003;63:2307-16. [PMID: 14524732 DOI: 10.2165/00003495-200363210-00003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
49 Bixquert M. Maintenance Therapy in Gastro-oesophageal Reflux Disease: . Drugs 2005;65:59???66. [DOI: 10.2165/00003495-200565001-00009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
50 Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, Thursz MR, Campbell MK. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ. 2008;337:a2664. [PMID: 19074946 DOI: 10.1136/bmj.a2664] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 4.9] [Reference Citation Analysis]
51 de Veer AJ, Bos JT, Niezen-de Boer RC, Böhmer CJ, Francke AL. Symptoms of gastroesophageal reflux disease in severely mentally retarded people: a systematic review. BMC Gastroenterol 2008;8:23. [PMID: 18547405 DOI: 10.1186/1471-230X-8-23] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
52 Mostaghni A, Mehrabani D, Khademolhosseini F, Masoumi SJ, Moradi F, Zare N, Saberi-Firoozi M. Prevalence and risk factors of gastroesophageal reflux disease in Qashqai migrating nomads, southern Iran. World J Gastroenterol 2009; 15(8): 961-965 [PMID: 19248195 DOI: 10.3748/wjg.15.961] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
53 Raghunath A, Hungin A, Cornford C, Featherstone V. Use of Proton Pump Inhibitors: An Exploration of the Attitudes, Knowledge and Perceptions of General Practitioners. Digestion 2005;72:212-8. [DOI: 10.1159/000089727] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
54 Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK. Pharmacoeconomics 2002;20:279-87. [PMID: 11950384 DOI: 10.2165/00019053-200220040-00006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
55 Dantas RO, Aprile LR. Esophageal striated muscle contractions in patients with gastroesophageal reflux symptoms. Dig Dis Sci 2002;47:2586-90. [PMID: 12452399 DOI: 10.1023/a:1020536815573] [Cited by in Crossref: 21] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
56 Marzo M, Alonso P, Bonfill X, Fernández M, Fernández J, Martínez G, Mearín F, Mascort J, Piqué J, Ponce J, Sáez M. Guía de práctica clínica sobre el manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Gastroenterología y Hepatología 2002;25:85-110. [DOI: 10.1016/s0210-5705(02)70245-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
57 Talley NJ. What the physician needs to know for correct management of gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 2004;20 Suppl 2:23-30. [PMID: 15335410 DOI: 10.1111/j.1365-2036.2004.02043.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
58 Mattioli S, Lugaresi ML, Costantini M, Del Genio A, Di Martino N, Fei L, Fumagalli U, Maffettone V, Monaco L, Morino M, Rebecchi F, Rosati R, Rossi M, Santi S, Trapani V, Zaninotto G. The short esophagus: intraoperative assessment of esophageal length. J Thorac Cardiovasc Surg 2008;136:834-41. [PMID: 18954619 DOI: 10.1016/j.jtcvs.2008.06.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
59 Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086-2100. [PMID: 16798392 DOI: 10.1016/s0140-6736(06)68932-0] [Cited by in Crossref: 270] [Cited by in F6Publishing: 93] [Article Influence: 16.9] [Reference Citation Analysis]
60 Orr WC. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. European Journal of Gastroenterology & Hepatology 2005;17:113-20. [DOI: 10.1097/00042737-200501000-00021] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
61 Miyamoto M, Manabe N, Haruma K. Frequency scale for symptoms of gastroesophageal reflux disease questionnaire predicts requirement of proton pump inhibitor maintenance therapy. Esophagus 2010;7:143-9. [DOI: 10.1007/s10388-010-0245-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Giannini EG, Zentilin P, Dulbecco P, Vigneri S, Scarlata P, Savarino V. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol. 2008;103:267-275. [PMID: 18289194 DOI: 10.1111/j.1572-0241.2007.01659.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
63 Vandvik PO, Kristensen P, Aabakken L, Farup PG. Abdominal complaints in general practice Diagnoses and characteristics of patients. Scandinavian Journal of Primary Health Care 2009;22:157-62. [DOI: 10.1080/02813430410006503] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
64 Jeong YJ, Lee DH, Choi TH, Hwang TJ, Lee BH, Nah JC, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Kim N, Jung HC, Song IS. [Clinical analysis of recurrence rate and symptom improvement in gastro-esophageal reflux disease patients]. Korean J Gastroenterol 2010;55:100-8. [PMID: 20168056 DOI: 10.4166/kjg.2010.55.2.100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
65 Miele L, Cammarota G, Vero V, Racco S, Cefalo C, Marrone G, Pompili M, Rapaccini G, Bianco A, Landolfi R, Gasbarrini A, Grieco A. Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Dig Liver Dis 2012;44:1032-6. [PMID: 22963909 DOI: 10.1016/j.dld.2012.08.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]